SGLT-2 inhibitor administration in hypertrophic cardiomyopathy patients was associated with improved left ventricular diastolic function and NYHA class over a 16.3-month median follow-up.
Observational
Does SGLT-2i improve cardiac function and NYHA class in patients with hypertrophic cardiomyopathy?
SGLT-2 inhibitors may improve diastolic function and symptoms in patients with hypertrophic cardiomyopathy without increasing renal or hypoglycemic risks.
p-value: p== 0.73
Background and aims: Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy and diastolic dysfunction. While sodium-glucose cotransporter 2 inhibitors (SGLT-2i) have demonstrated efficacy in heart failure (HF), their role in HCM remains underexplored. This real-world study aimed to evaluate the clinical efficacy of SGLT-2i in HCM patients. Methods and results: = 0.73) after 16.3-month median follow-up. No hypoglycemic events occurred and there was no significant deterioration in renal function. Conclusion: SGLT-2i administration was associated with improved left ventricular diastolic function and NYHA class in HCM patients without increasing risks of renal dysfunction or hypoglycemia, supporting its potential therapeutic value in this population.
Ding et al. (Thu,) conducted a observational in Hypertrophic cardiomyopathy. SGLT-2 inhibitors was evaluated on Left ventricular diastolic function and NYHA class (p== 0.73). SGLT-2 inhibitor administration in hypertrophic cardiomyopathy patients was associated with improved left ventricular diastolic function and NYHA class over a 16.3-month median follow-up.